Medicenna Therapeutics (TSE:MDNA) Reaches New 12-Month Low – Time to Sell?

Medicenna Therapeutics Corp. (TSE:MDNA) hit a new 52-week low on Tuesday . The company traded as low as C$0.42 and last traded at C$0.44, with a volume of 105945 shares changing hands. The stock had previously closed at C$0.45.

Medicenna Therapeutics Stock Down 2.2%

The company has a market cap of C$36.70 million, a P/E ratio of -2.93 and a beta of 2.90. The stock has a 50-day moving average of C$0.61 and a two-hundred day moving average of C$0.91. The company has a debt-to-equity ratio of 3.30, a quick ratio of 4.65 and a current ratio of 2.68.

Medicenna Therapeutics (TSE:MDNA) last issued its quarterly earnings results on Thursday, April 30th. The company reported C($0.06) EPS for the quarter. Medicenna Therapeutics had a negative net margin of 533,640.00% and a negative return on equity of 103.51%. On average, research analysts anticipate that Medicenna Therapeutics Corp. will post -0.37 EPS for the current fiscal year.

Medicenna Therapeutics Company Profile

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment. The have the potential to purge the tumor and un-blind the immune system to cancer thereby altering the treatment paradigm for a large majority of cancer patients.